论文部分内容阅读
目的探讨西格列汀联合格列美脲治疗2型糖尿病的疗效。方法将38例2型糖尿病患者随机分为二组,治疗组18例,用西格列汀联合格列美脲进行治疗,对照组20例应用格列美脲单药治疗,观察12周。比较二组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)、低血糖发生率、体重指数(BMI)变化情况。结果治疗12周后,治疗组与对照组的FBG、2hPG、HbA1c、BMI均明显下降,但联合治疗组的各项指标更接近理想目标。结论西格列汀联合格列美脲治疗2型糖尿病疗效确切,且有效控制患者体重,但增加了低血糖事件发生率。
Objective To investigate the effect of sitagliptin and glimepiride in the treatment of type 2 diabetes. Methods Thirty-eight patients with type 2 diabetes were randomly divided into two groups. The treatment group (n = 18) was treated with sitagliptin and glimepiride. The control group (n = 20) was treated with glimepiride alone for 12 weeks. The changes of fasting blood glucose (FBG), 2h postprandial blood glucose (2hPG), HbA1c, the incidence of hypoglycemia and body mass index (BMI) were compared between the two groups before and after treatment. Results After 12 weeks of treatment, the FBG, 2hPG, HbA1c and BMI in the treatment group and the control group were significantly decreased, but the combination therapy group indicators closer to the desired goal. Conclusion Sitagliptin combined with glimepiride in the treatment of type 2 diabetes is effective and effective in controlling the weight of patients, but increases the incidence of hypoglycemic events.